Article Details

Syngene Q1 PAT increases 33% yoy to Rs77cr; Stock under pressure

Retrieved on: 2021-07-22 06:33:45

Tags for this article:

Click the tags to see associated articles and topics

Syngene Q1 PAT increases 33% yoy to Rs77cr; Stock under pressure. View article details on hiswai:

Excerpt

... in the first quarter was also boosted by the manufacturing of Remdesivir to fulfill the high demand for the drug from Indian healthcare providers.

Article found on: www.indiainfoline.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up